JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

Search

Pfizer

Fechado

SetorSaúde

24.59 0.04

Visão Geral

Variação de preço das ações

24h

Atual

Mín

24.55

Máximo

24.87

Indicadores-chave

By Trading Economics

Rendimento

2.6B

3B

Vendas

-4B

14B

P/E

Médio do Setor

17.051

34.393

EPS

0.92

Rendimento de Dividendos

7.19

Margem de lucro

21.677

Funcionários

81,000

EBITDA

2.5B

5.1B

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+16.31% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

7.19%

2.54%

Próximos Ganhos

28 de out. de 2025

Próxima data de dividendos

2 de set. de 2025

Próxima data de ex-dividendo

7 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-12B

134B

Abertura anterior

24.55

Fecho anterior

24.59

Sentimento de Notícias

By Acuity

39%

61%

125 / 374 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

Pfizer Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

5 de ago. de 2025, 11:34 UTC

Ganhos

Pfizer Boosts 2025 Adjusted EPS Outlook Following 2Q Gains

5 de ago. de 2025, 20:44 UTC

Ganhos

These Stocks Moved the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5 de ago. de 2025, 18:20 UTC

Ganhos

Pfizer Stock Rises as Earnings Smash Expectations. But These Challenges Remain. -- Barrons.com

5 de ago. de 2025, 18:17 UTC

Ganhos

These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5 de ago. de 2025, 16:04 UTC

Conversa de Mercado

Pfizer's New Tax Rate Helps Boost Adj EPS Outlook -- Market Talk

5 de ago. de 2025, 15:25 UTC

Ganhos

Correction to These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Caterpillar, BP, and More -- Barrons.com

5 de ago. de 2025, 13:56 UTC

Ganhos

Pfizer Stock Rises as Earnings Smash Expectations. But These Challenges Remain. -- Barrons.com

5 de ago. de 2025, 11:43 UTC

Ganhos

Pfizer Stock Pops as Earnings Smash Expectations. Guidance Hiked in Face of Tariffs. -- Barrons.com

5 de ago. de 2025, 11:27 UTC

Ganhos

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5 de ago. de 2025, 10:57 UTC

Ganhos

Pfizer Stock Pops as Earnings Smash Expectations. Why the Outlook Has Been Hiked. -- Barrons.com

5 de ago. de 2025, 10:55 UTC

Ganhos

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5 de ago. de 2025, 10:53 UTC

Ganhos

Pfizer Boosts 2025 Profit Estimate In A Sign Of 'Confidence' -- MarketWatch

5 de ago. de 2025, 10:51 UTC

Ganhos

Pfizer: On Track to Deliver About $7.2B Overall Cost Savings From Cost-Improvement Initiatives b/ End of 2027 >PFE

5 de ago. de 2025, 10:50 UTC

Ganhos

Pfizer: Expects to Continue to De-Lever in Prudent Manner to Maintain Balanced Capital-Allocation Strategy >PFE

5 de ago. de 2025, 10:49 UTC

Ganhos

Pfizer: Current Financial Guidance Doesn't Anticipate Any Share Repurchases in 2025 >PFE

5 de ago. de 2025, 10:49 UTC

Ganhos

Pfizer Now Sees 2025 Effective Tax Rate on Adjusted Income About 13%; Had Seen About 15% >PFE

5 de ago. de 2025, 10:48 UTC

Ganhos

Pfizer Cuts Adjusted R&D Expenses View to $10.4-$11.4B From $10.7B-$11.7B >PFE

5 de ago. de 2025, 10:48 UTC

Ganhos

Pfizer: Guidance Absorbs Impact of Potential Price Changes This Year Based on Letter Received July 31 From President Trump >PFE

5 de ago. de 2025, 10:47 UTC

Ganhos

Pfizer: Guidance Absorbs Impact of Currently Imposed Tariffs From China, Canada, Mexico >PFE

5 de ago. de 2025, 10:46 UTC

Ganhos

Pfizer Had Seen 2025 Adjusted EPS $2.80-$3.00 >PFE

5 de ago. de 2025, 10:45 UTC

Ganhos

Pfizer Raises 2025 EPS Guidance >PFE

5 de ago. de 2025, 10:45 UTC

Ganhos

Pfizer 2Q EPS 51c >PFE

5 de ago. de 2025, 10:45 UTC

Ganhos

Pfizer Sees FY Adj EPS $2.90-Adj EPS $3.10 >PFE

5 de ago. de 2025, 10:45 UTC

Ganhos

Pfizer 2Q Adj EPS 78c >PFE

5 de ago. de 2025, 10:45 UTC

Ganhos

Pfizer 2Q Rev $14.7B >PFE

5 de ago. de 2025, 10:45 UTC

Ganhos

Pfizer Sees FY Rev $61B-$64B >PFE

4 de ago. de 2025, 15:26 UTC

Ganhos

Pfizer Reports Earnings Soon. The Stock Is Slumping for a Reason. -- Barrons.com

30 de jul. de 2025, 18:36 UTC

Ganhos

UPS Stock Joins 7% Yielders in S&P 500. Here's Who Else Is in the Club. -- Barrons.com

9 de jul. de 2025, 09:17 UTC

Ações em Alta

Stocks to Watch Wednesday: Freeport-McMoRan, Glencore, Novo Nordisk -- WSJ

10 de jun. de 2025, 12:18 UTC

Ganhos

Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors. -- Barrons.com

Comparação entre Pares

Variação de preço

Pfizer Previsão

Preço-alvo

By TipRanks

16.31% parte superior

Previsão para 12 meses

Média 28.59 USD  16.31%

Máximo 33 USD

Mínimo 24 USD

Com base em 18 analistas de Wall Street que oferecem metas de preço de 12 meses para Pfizer - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

18 ratings

6

Comprar

12

Manter

0

Vender

Pontuação Técnica

By Trading Central

22.855 / 23.85Suporte e Resistência

Curto Prazo

Bullish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

125 / 374 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.